Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Osteoporosis International
Published in: Osteoporosis International 8/2019

Open Access 01-08-2019 | Glucocorticoid | Original Article

Abaloparatide increases bone mineral density and bone strength in ovariectomized rabbits with glucocorticoid-induced osteopenia

Authors: H. Chandler, D.J. Brooks, G. Hattersley, M.L. Bouxsein, B. Lanske

Published in: Osteoporosis International | Issue 8/2019

Login to get access

Abstract

Summary

Glucorticoid (GC) therapy is the commonest cause of secondary osteoporosis. Ovariectomized rabbits receiving the GC methylprednisolone for 6 weeks exhibited relatively lower vertebral and femoral bone mass. Treatment with the PTH receptor agonist abaloparatide for 12 weeks during ongoing methylprednisolone administration increased cortical and trabecular bone mass and femur bending strength.

Introduction

Abaloparatide, an osteoanabolic PTHrP analog, increases bone mineral density (BMD) and reduces fracture risk in women with postmenopausal osteoporosis. This study assessed abaloparatide effects on BMD and bone strength in ovariectomized (OVX) rabbits with glucocorticoid (GC)-induced osteopenia.

Methods

Thirty-two rabbits underwent OVX and 8 underwent sham surgery. One day later, 24 OVX rabbits began daily s.c. GC injections (methylprednisolone, 1 mg/kg/day) for 6 weeks, while 8 OVX and 8 sham controls received no GC. GC-challenged rabbits (8/group) then received GC (0.5 mg/kg/day) along with daily s.c. vehicle (GC-OVX), abaloparatide 5 μg/kg/day (ABL5), or 25 μg/kg/day (ABL25) for 12 weeks, and the no-GC OVX and sham controls received daily vehicle.

Results

GC-OVX rabbits showed significant deficits in vertebral and proximal femur areal BMD, lower cortical area, thickness and volumetric BMD of the femur diaphysis, and reduced trabecular bone volume and volumetric BMD in the vertebra and distal femur versus sham controls. These deficits were significantly reversed in the ABL25 group, which also showed enhanced trabecular micro-architecture versus GC-OVX controls. Destructive bending tests showed significantly lower femur diaphysis ultimate load and bending rigidity of the femoral diaphysis in the GC-OVX group versus sham controls, whereas these parameters were similar in the ABL25 group vs sham controls.

Conclusions

Abaloparatide 25 μg/kg/day mitigated the adverse effects of GC administration on cortical and trabecular bone and improved femoral strength in OVX rabbits. These results suggest potential promise for abaloparatide as an investigational therapy for glucocorticoid-induced osteoporosis.
Literature
1.
2.
Canalis E, Mazziotti G, Giustina A, Bilezikian JP (2007) Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int 18(10):1319–1328CrossRefPubMed
3.
Chappard D, Josselin N, Rouge-Maillart C, Legrand E, Basle MF, Audran M (2007) Bone microarchitecture in males with corticosteroid-induced osteoporosis. Osteoporos Int 18(4):487–494CrossRefPubMed
4.
Piemontese M, Xiong J, Fujiwara Y, Thostenson JD, O'Brien CA (2016) Cortical bone loss caused by glucocorticoid excess requires RANKL production by osteocytes and is associated with reduced OPG expression in mice. Am J Physiol Endocrinol Metab 311(3):E587–E593CrossRefPubMedPubMedCentral
5.
Vedi S, Elkin SL, Compston JE (2005) A histomorphometric study of cortical bone of the iliac crest in patients treated with glucocorticoids. Calcif Tissue Int 77(2):79–83CrossRefPubMed
6.
7.
Miao D, He B, Jiang Y, Kobayashi T, Sorocéanu MA, Zhao J, Su H, Tong X, Amizuka N, Gupta A, Genant HK, Kronenberg HM, Goltzman D, Karaplis AC (2005) Osteoblast-derived PTHrP is a potent endogenous bone anabolic agent that modifies the therapeutic efficacy of administered PTH 1-34. J Clin Invest 115(9):2402–2411CrossRefPubMedPubMedCentral
8.
Walsh CA, Birch MA, Fraser WD, Lawton R, Dorgan J, Walsh S, Sansom D, Beresford JN, Gallagher JA (1995) Expression and secretion of parathyroid hormone-related protein by human bone-derived cells in vitro: effects of glucocorticoids. J Bone Miner Res 10(1):17–25CrossRefPubMed
9.
Ahlstrom M, Pekkinen M, Lamberg-Allardt C (2009) Dexamethasone downregulates the expression of parathyroid hormone-related protein (PTHrP) in mesenchymal stem cells. Steroids 74(2):277–282CrossRefPubMed
10.
de Castro LF, Lozano D, Dapia S, Portal-Nunez S, Caeiro JR, Gomez-Barrena E, Esbrit P (2010) Role of the N- and C-terminal fragments of parathyroid-hormone-related protein as putative therapies to improve bone regeneration under high glucocorticoid treatment. Tissue Eng Part A 16(4):1157–1168CrossRefPubMed
11.
Saag KG, Zanchetta JR, Devogelaer JP, Adler RA, Eastell R, See K, Krege JH, Krohn K, Warner MR (2009) Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum 60(11):3346–3355CrossRefPubMed
12.
Bostrom MP, Gamradt SC, Asnis P, Vickery BH, Hill E, Avnur Z, Waters RV (2000) Parathyroid hormone-related protein analog RS-66271 is an effective therapy for impaired bone healing in rabbits on corticosteroid therapy. Bone 26(5):437–442CrossRefPubMed
13.
Miller PD, Hattersley G, Riis BJ, Williams GC, Lau E, Russo LA, Alexandersen P, Zerbini CAF, Hu MY, Harris AG, Fitzpatrick LA, Cosman F, Christiansen C, for the ACTIVE Study Investigators (2016) Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial. JAMA 316(7):722–733CrossRefPubMed
14.
Cosman F, Miller PD, Williams GC, Hattersley G, Hu MY, Valter I, Fitzpatrick LA, Riis BJ, Christiansen C, Bilezikian JP, Black D (2017) Eighteen months of treatment with subcutaneous abaloparatide followed by 6 months of treatment with alendronate in postmenopausal women with osteoporosis:Results of the ACTIVExtend trial. Mayo Clin Proc 92(2):200–210CrossRefPubMed
15.
Bahar H, Gallacher K, Downall J, Nelson CA, Shomali M, Hattersley G (2016) Six weeks of daily abaloparatide treatment increased vertebral and femoral bone mineral density, microarchitecture and strength in ovariectomized osteopenic rats. Calcif Tissue Int 99(5):489–499CrossRefPubMedPubMedCentral
16.
Varela A, Chouinard L, Lesage E, Guldberg R, Smith SY, Kostenuik PJ, Hattersley G (2017) One year of abaloparatide, a selective peptide activator of the PTH1 receptor, increased bone mass and strength in ovariectomized rats. Bone 95:143–150CrossRefPubMed
17.
Varela A, Chouinard L, Lesage E, Smith SY, Hattersley G (2017) One year of abaloparatide, a selective activator of the PTH1 receptor, increased bone formation and bone mass in osteopenic ovariectomized rats without increasing bone resorption. J Bone Miner Res 32(1):24–33CrossRefPubMed
18.
Doyle N, Varela A, Haile S, Guldberg R, Kostenuik PJ, Ominsky MS, Smith SY, Hattersley G (2018) Abaloparatide, a novel PTH receptor agonist, increased bone mass and strength in ovariectomized cynomolgus monkeys by increasing bone formation without increasing bone resorption. Osteoporos Int 29(3):685–697CrossRefPubMed
19.
Chandler H, Lanske B, Varela A, Guillot M, Boyer M, Brown J, Pierce A, Ominsky M, Mitlak B, Baron R, Kostenuik P, Hattersley G (2019) Abaloparatide, a novel osteoanabolic PTHrP analog, increases cortical and trabecular bone mass and architecture in orchiectomized rats by increasing bone formation without increasing bone resorption. Bone 120:148–155CrossRefPubMed
20.
Bouxsein ML, Boyd SK, Christiansen BA, Guldberg RE, Jepsen KJ, Muller R (2010) Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. J Bone Miner Res 25(7):1468–1486CrossRefPubMed
21.
Cacchioli A, Ravanetti F, Soliani L, Borghetti P (2012) Preliminary study on the mineral apposition rate in distal femoral epiphysis of New Zealand white rabbit at skeletal maturity. Anat Histol Embryol 41(3):163–169CrossRefPubMed
22.
Mawatari T, Miura H, Hamai S, Shuto T, Nakashima Y, Okazaki K, Kinukawa N, Sakai S, Hoffmann PF, Iwamoto Y, Keaveny TM (2008) Vertebral strength changes in rheumatoid arthritis patients treated with alendronate, as assessed by finite element analysis of clinical computed tomography scans: a prospective randomized clinical trial. Arthritis Rheum 58(11):3340–3349CrossRefPubMed
23.
Castaneda S, Calvo E, Largo R, Gonzalez-Gonzalez R, de la Piedra C, Diaz-Curiel M, Herrero-Beaumont G (2008) Characterization of a new experimental model of osteoporosis in rabbits. J Bone Miner Metab 26(1):53–59CrossRefPubMed
24.
Eberhardt AW, Yeager-Jones A, Blair HC (2001) Regional trabecular bone matrix degeneration and osteocyte death in femora of glucocorticoid- treated rabbits. Endocrinology 142(3):1333–1340CrossRefPubMed
25.
Baofeng L, Zhi Y, Bei C, Guolin M, Qingshui Y, Jian L (2010) Characterization of a rabbit osteoporosis model induced by ovariectomy and glucocorticoid. Acta Orthop 81(3):396–401CrossRefPubMedPubMedCentral
26.
27.
Almagro MI, Roman-Blas JA, Bellido M, Castaneda S, Cortez R, Herrero-Beaumont G (2013) PTH [1-34] enhances bone response around titanium implants in a rabbit model of osteoporosis. Clin Oral Implants Res 24(9):1027–1034PubMed
28.
Hirano T, Burr DB, Cain RL, Hock JM (2000) Changes in geometry and cortical porosity in adult, ovary-intact rabbits after 5 months treatment with LY333334 (hPTH 1-34). Calcif Tissue Int 66(6):456–460CrossRefPubMed
29.
Yamane H, Takakura A, Shimadzu Y, Kodama T, Lee JW, Isogai Y, Ishizuya T, Takao-Kawabata R, Iimura T (2017) Acute development of cortical porosity and endosteal naive bone formation from the daily but not weekly short-term administration of PTH in rabbit. PLoS One 12(4):e0175329CrossRefPubMedPubMedCentral
30.
Bagi CM, Berryman E, Moalli MR (2011) Comparative bone anatomy of commonly used laboratory animals: implications for drug discovery. Comp Med 61(1):76–85PubMedPubMedCentral
Metadata
Title
Abaloparatide increases bone mineral density and bone strength in ovariectomized rabbits with glucocorticoid-induced osteopenia
Authors
H. Chandler
D.J. Brooks
G. Hattersley
M.L. Bouxsein
B. Lanske
Publication date
01-08-2019
Publisher
Springer London
Published in
Osteoporosis International / Issue 8/2019
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-019-04999-4

Other articles of this Issue 8/2019

Osteoporosis International 8/2019 Go to the issue

Obituary

Professor Howard A. Morris

Letter to the Editor

Glucagon-like peptide-1 receptor agonists and fracture risk—limitations to current knowledge

Original Article

Effects of zoledronic acid on bone mineral density around prostheses and bone metabolism markers after primary total hip arthroplasty in females with postmenopausal osteoporosis

Case Report

Diffuse osteosclerosis as a presentation of recurrent breast cancer: role of endothelin 1

Review Article

Effect of vitamin K on bone mineral density and fractures in adults: an updated systematic review and meta-analysis of randomised controlled trials

Letter to the Editor

Reply to “Antiretroviral therapy options in people living with HIV at risk of or with osteoporosis. Comment on: Diagnosis, prevention, and treatment of bone fragility in people living with HIV: a position statement from the Swiss Association against Osteoporosis” by S. Noe, H. Jaeger, E. Wolf